Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 140000
Corporate User License Price USD 6000
Corporate User License Price INR 420000
Site License Price USD 4000
Site License Price INR 280000
Request a Quote

Report Title

Thyroid Cancer-Pipeline Review, H2 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Thyroid Cancer-Pipeline Review, H2 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Thyroid Cancer-Pipeline Review, H2 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Thyroid Cancer-Pipeline Review, H2 2017



Executive Summary

Thyroid Cancer-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thyroid Cancer-Pipeline Review, H2 2017, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape.

Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through the skin on neck, difficulty swallowing, pain in neck and throat and swollen lymph nodes in neck. Predisposing factors include female, high levels of radiation and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thyroid Cancer-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 33, 28, 1, 11 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 5 molecules, respectively.

Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Thyroid Cancer (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 5

Thyroid Cancer-Overview 6

Thyroid Cancer-Therapeutics Development 7

Thyroid Cancer-Therapeutics Assessment 20

Thyroid Cancer-Companies Involved in Therapeutics Development 32

Thyroid Cancer-Drug Profiles 55

Thyroid Cancer-Dormant Projects 465

Thyroid Cancer-Discontinued Products 467

Thyroid Cancer-Product Development Milestones 468

Appendix 480

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Thyroid Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

List of Tables

Number of Products under Development for Thyroid Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Thyroid Cancer-Pipeline by AbbVie Inc, H2 2017

Thyroid Cancer-Pipeline by Advenchen Laboratories LLC, H2 2017

Thyroid Cancer-Pipeline by AstraZeneca Plc, H2 2017

Thyroid Cancer-Pipeline by Bayer AG, H2 2017

Thyroid Cancer-Pipeline by BeiGene Ltd, H2 2017

Thyroid Cancer-Pipeline by Biovista Inc, H2 2017

Thyroid Cancer-Pipeline by Blueprint Medicines Corp, H2 2017

Thyroid Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2017

Thyroid Cancer-Pipeline by Bristol-Myers Squibb Company, H2 2017

Thyroid Cancer-Pipeline by Celldex Therapeutics Inc, H2 2017

Thyroid Cancer-Pipeline by Centrose LLC, H2 2017

Thyroid Cancer-Pipeline by Curis Inc, H2 2017

Thyroid Cancer-Pipeline by Cytori Therapeutics Inc, H2 2017

Thyroid Cancer-Pipeline by Daiichi Sankyo Company Ltd, H2 2017

Thyroid Cancer-Pipeline by Ecrins Therapeutics SAS, H2 2017

Thyroid Cancer-Pipeline by Eisai Co Ltd, H2 2017

Thyroid Cancer-Pipeline by Ensol Biosciences Inc, H2 2017

Thyroid Cancer-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Thyroid Cancer-Pipeline by Genelux Corp, H2 2017

Thyroid Cancer-Pipeline by Genmab A/S, H2 2017

Thyroid Cancer-Pipeline by GlaxoSmithKline Plc, H2 2017

Thyroid Cancer-Pipeline by Gradalis Inc, H2 2017

Thyroid Cancer-Pipeline by Hutchison MediPharma Ltd, H2 2017

Thyroid Cancer-Pipeline by Ignyta Inc, H2 2017

Thyroid Cancer-Pipeline by Immune Pharmaceuticals Inc, H2 2017

Thyroid Cancer-Pipeline by Immunomedics Inc, H2 2017

Thyroid Cancer-Pipeline by Johnson & Johnson, H2 2017

Thyroid Cancer-Pipeline by Konruns Pharmaceutical Co Ltd, H2 2017

Thyroid Cancer-Pipeline by Loxo Oncology Inc, H2 2017

Thyroid Cancer-Pipeline by MacroGenics Inc, H2 2017

Thyroid Cancer-Pipeline by MaxiVAX SA, H2 2017

Thyroid Cancer-Pipeline by MedImmune LLC, H2 2017

Thyroid Cancer-Pipeline by Merck & Co Inc, H2 2017

Thyroid Cancer-Pipeline by Merck KGaA, H2 2017

Thyroid Cancer-Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Thyroid Cancer-Pipeline by Nerviano Medical Sciences Srl, H2 2017

Thyroid Cancer-Pipeline by Novartis AG, H2 2017

Thyroid Cancer-Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Thyroid Cancer-Pipeline by Pfizer Inc, H2 2017

Thyroid Cancer-Pipeline by Plexxikon Inc, H2 2017

Thyroid Cancer-Pipeline by Rodos BioTarget GmbH, H2 2017

Thyroid Cancer-Pipeline by Synactix Pharmaceuticals Inc, H2 2017

Thyroid Cancer-Pipeline by Tarveda Therapeutics Inc, H2 2017

Thyroid Cancer-Pipeline by Vaccinex Inc, H2 2017

Thyroid Cancer-Pipeline by Vascular Biogenics Ltd, H2 2017

Thyroid Cancer-Pipeline by XSpray Microparticles AB, H2 2017

Thyroid Cancer-Dormant Projects, H2 2017

Thyroid Cancer-Dormant Projects, H2 2017 (Contd..1), H2 2017

Thyroid Cancer-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

AbbVie Inc

Advenchen Laboratories LLC

AstraZeneca Plc

Bayer AG

BeiGene Ltd

Biovista Inc

Blueprint Medicines Corp

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celldex Therapeutics Inc

Centrose LLC

Curis Inc

Cytori Therapeutics Inc

Daiichi Sankyo Company Ltd

Ecrins Therapeutics SAS

Eisai Co Ltd

Ensol Biosciences Inc

F. Hoffmann-La Roche Ltd

Genelux Corp

Genmab A/S

GlaxoSmithKline Plc

Gradalis Inc

Hutchison MediPharma Ltd

Ignyta Inc

Immune Pharmaceuticals Inc

Immunomedics Inc

Johnson & Johnson

Konruns Pharmaceutical Co Ltd

Loxo Oncology Inc

MacroGenics Inc

MaxiVAX SA

MedImmune LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Nerviano Medical Sciences Srl

Novartis AG

Ono Pharmaceutical Co Ltd

Pfizer Inc

Plexxikon Inc

Rodos BioTarget GmbH

Synactix Pharmaceuticals Inc

Tarveda Therapeutics Inc

Vaccinex Inc

Vascular Biogenics Ltd

XSpray Microparticles AB

Thyroid Cancer Therapeutic Products under Development, Key Players in Thyroid Cancer Therapeutics, Thyroid Cancer Pipeline Overview, Thyroid Cancer Pipeline, Thyroid Cancer Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person